Quantcast

Industry news that matters to you.  Learn more

Launch of Consumer Health Intelligence Service Onegevity Combines Blood, Genome and Microbiome Analysis for Personalized Health and Wellness

January 15 marks the official launch of Onegevity Health as a new consumer health intelligence company, which combines a multi-omic artificial intelligence (AI) platform with consumer-friendly products and digital services. Onegevity will provide a comprehensive molecular portrait and customized recommendations for an individual’s health based on integrated analysis of longitudinal blood, genetics, and gut microbiome profiles.

New Asthma Biomarkers Identified from Lung Bacteria

While the microbiome has gained significant attention for its impact on digestive health in recent years, its effect on lung disease has largely remained unstudied. Dr. Patricia Finn says this is a missed opportunity. “The microbiome is the ecosystem of good and bad bacteria living in the body,” said Finn, the Earl M. Bane Professor of Medicine at the University of Illinois at Chicago. “Because the lungs continuously and automatically draw air, and any number of environmental agents, into the body, the composition and balance of microbes in the lungs may have a profound effect on many respiratory conditions.” New research from Finn and her colleagues in the UIC College of Medicine suggests that the lung microbiome plays a significant role in asthma severity and response to treatment.

Gut Microbiota: A New Kind of Biomarker?

The composition of the gut microbiota provides a huge potential of new biomarkers for indicating intestinal conditions. Experts presented new findings at the Gut Microbiota for Health World Summit 2016 (March 5/6, Miami).

Human Longevity, Inc. Signs Collaborative Agreement with King’s College London to Access TwinsUK Registry

Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, recently announced a collaborative agreement with King’s College London to access their TwinsUK Registry.

Enterome Enters into a Microbiome-Based Development Collaboration with AbbVie in Crohn’s Disease

ENTEROME Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a thorough understanding of the gut microbiome, recently announced that it has entered into a collaborative development agreement with AbbVie. The alliance is anchored around Enterome’s proprietary metagenomic biomarker portfolio and technologies that may enable the development of novel diagnostic products to support personalized therapies and the development of new drugs in microbiome-related diseases.